Interventional procedure overview of endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes
Closed for comments This consultation ended on at Request commenting lead permission
Table 1 Abbreviations
Abbreviation | Definition |
|---|---|
ABPM | Ambulatory 24 h blood pressure monitoring |
AE | Adverse event |
ALT | Alanine aminotransferase |
ASCVD | Atherosclerotic cardiovascular disease |
AST | Aspartate aminotransferase |
BMI | Body mass index |
DIAL | Diabetes lifetime-perspective prediction |
DMR | Duodenal mucosal resurfacing |
DTSQ | Diabetes Treatment Satisfaction Questionnaire |
FPG | Fasting plasma glucose |
FPI | Fasting plasma insulin |
GI | Gastrointestinal |
GLP-1/GLP-1RA | Glucagon-like peptide-1 (receptor agonists) |
HDL | High-density lipoprotein |
HOMA-IR | Homeostatic Model Assessment Index for Insulin Resistance |
IQR | Interquartile range |
LDL | Low-density lipoprotein |
LS-DMR | Long segment ablation (about 9.3 cm treated) for duodenal mucosal resurfacing |
MAP | Mean arterial pressure |
mITT | Modified intention-to-treat |
PDFF | Proton density fat function |
PP | Per protocol |
RCT | Randomised controlled trial |
SAE | Serious adverse event |
SAT | Subcutaneous adipose tissue |
SD | Standard deviation |
SS-DMR | Short segment ablation (about 3.4 cm treated) for duodenal mucosal resurfacing |
T2D | Type 2 diabetes (mellitus) |
VAT | Visceral adipose tissue |
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions